Synergy of the antibiotic colistin with echinocandin antifungals in candida species

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1285-1296

  Zeidler, Ute ^a,b   Bougnoux, Marie Elisabeth ^a,c   Lupan, Alexandru ^a,d   Helynck, Olivier ^a,d   Doyen, Antonia ^a,d   Garcia, Zacarias ^a   Sertour, Natacha ^a,b   Clavaud, Cécile ^a   Munier Lehmann, Hélène ^a,d   Saveanu, Cosmin ^a,d   d'Enfert, Christophe ^a,b  

^a INSTITUT PASTEUR   (France)

^b INRA F 75015   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d CNRS   (France)

Author keywords

Candida albicans; Caspofungin; Combination therapy; Polymyxin; Sp

Indexed keywords

AMINOCANDIN; CASPOFUNGIN; CHITIN; COLISTIMETHATE; COLISTIN; ECHINOCANDIN B DERIVATIVE; SPHINGOLIPID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOSYNTHESIS; CANDIDA; CANDIDA ALBICANS; CELL PERMEABILIZATION; CONTROLLED STUDY; DRUG PENETRATION; DRUG POTENTIATION; DRUG SCREENING; FUNGAL CELL; FUNGAL MEMBRANE; GENETIC SCREENING; MOUSE; NONHUMAN; SACCHAROMYCES CEREVISIAE; YEAST CELL;

CANDIDA ALBICANS; CASPOFUNGIN; COMBINATION THERAPY; POLYMYXIN; SPHINGOLIPIDS;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CELL MEMBRANE PERMEABILITY; CELL WALL; CHITIN; COLISTIN; COLORING AGENTS; DRUG SYNERGISM; ECHINOCANDINS; GENE LIBRARY; GENETIC FITNESS; GENOTYPE; INDICATOR DILUTION TECHNIQUES; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTATION; PROPIDIUM; SACCHAROMYCES CEREVISIAE; SPHINGOLIPIDS;

EID: 84883344088     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks538     Document Type: Article

References (71)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
2. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007; 45: 321-46.
3. Azie N, Neofytos D, Pfaller M et al. The PATH (Prospective Antifungal Therapy) Alliance(R) registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 2012; 73: 293-300.
4. Horn DL, Fishman JA, Steinbach WJ et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007; 59: 407-14.
5. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
6. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
7. Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52: 197-205.
8. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
9. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
10. Andes DR, Safdar N, Baddley JW et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54: 1110-22.
11. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 1983; 11: 427-33.
12. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61 Suppl 1: i19-30.
13. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10: 1545-8.
14. Newton BA. The properties and mode of action of the polymyxins. Bacteriol Rev 1956; 20: 14-27.
15. Nicholls MW. Polymyxin sensitivity of Candida tropicalis. J Med Microbiol 1970; 3: 529-38.
16. Schwartz SN, Medoff G, Kobayashi GS et al. Antifungal properties of polymyxin B and its potentiation of tetracycline as an antifungal agent. Antimicrob Agents Chemother 1972; 2: 36-40.
17. Moneib NA. In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. J Chemother 1995; 7: 525-9.
18. Zhai B, Zhou H, Yang L et al. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J Antimicrob Chemother 2010; 65: 931-8.
19. Ogita A, Konishi Y, Borjihan B et al. Synergistic fungicidal activities of polymyxin B and ionophores, and their dependence on direct disruptive action of polymyxin B on fungal vacuole. J Antibiot (Tokyo) 2009; 62: 81-7.
20. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
21. Johnson ME, Edlind TD. Topological and mutational analysis of Saccharomyces cerevisiae Fks1. Eukaryot Cell 2012; 11: 952-60.
22. Gillum AM, Tsay EY, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984; 198: 179-82.
23. Brachmann CB, Davies A, Cost GJ et al. Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast 1998; 14: 115-32.
24. Hibert MF. French/European academic compound library initiative. Drug Discov Today 2009; 14: 723-5.
25. Tiballi RN, He X, Zarins LT et al. Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol 1995; 33: 915-7.
26. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67-73.
27. Chatuverdi A, Green PE, Carroll JD. K-modes clustering. J Classif 2001; 18: 35-56.
28. Huang Z. Extensions to the k-means algorithm for clustering large data sets with categorical values. Data Min Knowl Discov 1998; 2: 283-304.
29. Willett P. Similarity and Clustering in Chemical Information Systems. Letchworth, UK: Research Studies Press Ltd, 1987.
30. Scott EM, Tariq VN, McCrory RM. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob Agents Chemother 1995; 39: 2610-4.
31. Giaever G, Chu AM, Ni L et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 2002; 418: 387-91.
32. Peyroche G, Saveanu C, Dauplais M et al. Sodium selenide toxicity is mediated by O2-dependent DNA breaks. PLoS ONE 2012; 7: e36343.
33. Gentleman RC, Carey VJ, Bates DM et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
34. Ben-Ami R, Lewis RE, Tarrand J et al. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother 2010; 54: 484-90.
35. Louie A, Deziel M, Liu Wet al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-68.
36. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
37. Vanden Bossche H, Koymans L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 1995; 67: 79-100.
38. Coste AT, Karababa M, Ischer F et al. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004; 3: 1639-52.
39. Hillenmeyer ME, Fung E, Wildenhain J et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 2008; 320: 362-5.
40. Uemura S, Kihara A, Iwaki S et al. Regulation of the transport and protein levels of the inositol phosphorylceramide mannosyltransferases Csg1 and Csh1 by the Ca2+-binding protein Csg2. J Biol Chem 2007; 282: 8613-21.
41. Uemura S, Kihara A, Inokuchi J et al. Csg1p and newly identified Csh1p function in mannosylinositol phosphorylceramide synthesis by interacting with Csg2p. J Biol Chem 2003; 278: 45049-555.
42. Dickson RC. Thematic review series: sphingolipids. New insights into sphingolipid metabolism and function in budding yeast. J Lipid Res 2008; 49: 909-21.
43. Dickson RC, Nagiec EE, Wells GB et al. Synthesis of mannose- (inositol-P)2-ceramide, the major sphingolipid in Saccharomyces cerevisiae, requires the IPT1 (YDR072c) gene. J Biol Chem1997; 272: 29620-5.
44. Oh CS, Toke DA, Mandala S et al. ELO2 and ELO3, homologues of the Saccharomyces cerevisiae ELO1 gene, function in fatty acid elongation and are required for sphingolipid formation. J Biol Chem1997; 272: 17376-84.
45. Cid VJ, Duran A, del Rey F et al. Molecular basis of cell integrity and morphogenesis in Saccharomyces cerevisiae. Microbiol Rev 1995; 59: 345-86.
46. Ziman M, Chuang JS, Tsung M et al. Chs6p-dependent anterograde transport of Chs3p from the chitosome to the plasma membrane in Saccharomyces cerevisiae. Mol Biol Cell 1998; 9: 1565-76.
47. Trilla JA, Duran A, Roncero C. Chs7p, a new protein involved in the control of protein export from the endoplasmic reticulum that is specifically engaged in the regulation of chitin synthesis in Saccharomyces cerevisiae. J Cell Biol 1999; 145: 1153-63.
48. DeMarini DJ, Adams AE, Fares H et al. A septin-based hierarchy of proteins required for localized deposition of chitin in the Saccharomyces cerevisiae cell wall. J Cell Biol 1997; 139: 75-93.
49. Lam KK, Davey M, Sun B et al. Palmitoylation by the DHHC protein Pfa4 regulates the ER exit of Chs3. J Cell Biol 2006; 174: 19-25.
50. Walker LA, Munro CA, de Bruijn I et al. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 2008; 4: e1000040.
51. Ozaki K, Tanaka K, Imamura H et al. Rom1p and Rom2p are GDP/GTP exchange proteins (GEPs) for the Rho1p small GTP binding protein in Saccharomyces cerevisiae. EMBO J 1996; 15: 2196-207.
52. Mille C, JanbonG,Delplace Fet al. Inactivationof CaMIT1 inhibits Candida albicans phospholipomannan b-mannosylation, reduces virulence, and alters cellwall protein b-mannosylation. J Biol Chem2004; 279: 47952-60.
53. Prasad T, Saini P, Gaur NA et al. Functional analysis of CaIPT1, a sphingolipid biosynthetic gene involved in multidrug resistance and morphogenesis of Candida albicans. Antimicrob Agents Chemother 2005; 49: 3442-52.
54. Noble SM, French S, Kohn LA et al. Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat Genet 2010; 42: 590-8.
55. Sanz M, Carrano L, Jimenez C et al. Candida albicans strains deficient in CHS7, a key regulator of chitin synthase III, exhibit morphogenetic alterations and attenuated virulence. Microbiology 2005; 151: 2623-36.
56. Bulawa CE, Miller DW, Henry LK et al. Attenuated virulence of chitin-deficient mutants of Candida albicans. Proc Natl Acad Sci USA 1995; 92: 10570-4.
57. Deere D, Shen J, Vesey G et al. Flow cytometry and cell sorting for yeast viability assessment and cell selection. Yeast 1998; 14: 147-60.
58. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
59. Harris MR, Coote PJ. Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents 2010; 35: 347-56.
60. Markovich S, Yekutiel A, Shalit I et al. Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2004; 48: 3871-6.
61. Lee KK, Maccallum DM, Jacobsen MD et al. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother 2010.
62. Lesage G, Sdicu AM, Menard P et al. Analysis of b-1,3-glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin. Genetics 2004; 167: 35-49.
63. Kiraz N, Dag I, Yamac M et al. Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods. Antimicrob Agents Chemother 2010; 54: 2244-7.
64. Oliveira ER, Fothergill AW, Kirkpatrick WR et al. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob Agents Chemother 2005; 49: 3544-5.
65. Roling EE, Klepser ME, Wasson A et al. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002; 43: 13-7.
66. Rossignol T, Kelly B, Dobson C et al. Endocytosis-mediated vacuolar accumulation of the human ApoE apolipoprotein-derived ApoEdpL-W antimicrobial peptide contributes to its antifungal activity in Candida albicans. Antimicrob Agents Chemother 2011; 55: 4670-81.
67. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50: 2058-63.
68. Karababa M, Coste AT, Rognon B et al. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob Agents Chemother 2004; 48: 3064-79.
69. Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in Candida albicans. Genetics 1993; 134: 717-28.
70. Noble SM, Johnson AD. Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans. Eukaryot Cell 2005; 4: 298-309.
71. Cherry JM, Hong EL, Amundsen C et al. Saccharomyces Genome Database: the genomics resource of budding yeast. Nucl Acids Res 2012; 40: D700-5.